About Moderately to Severely Active
Juvenile Idiopathic Arthritis (JIA)

Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children. JIA is defined as persistent arthritis in one or more joints that begins before age 16 and lasts at least 6 weeks. Some children have more than 5 affected joints. These children are said to have polyarticular JIA. ENBREL is indicated for moderately to severely active polyarticular JIA.

What causes JIA?

Although the exact cause of JIA is still unclear, juvenile idiopathic arthritis is believed to be a disease of the immune system. The immune system protects the body from infections and certain diseases. In JIA, the body's immune system attacks its own cells and tissues. It's unknown why this happens, but both heredity and environment seem to play a role. It is believed that, among many changes in the immune system, increased levels of a protein called tumor necrosis factor (TNF) play a role in the inflammation associated with JIA. Knowing how JIA develops can help you understand how some treatments, like ENBREL, work. Learn how ENBREL works in rheumatic conditions.

Symptoms of JIA

Unlike adult rheumatoid arthritis, juvenile idiopathic arthritis affects large joints like knees, wrists, and ankles more than small joints. However, the hands and feet may also be affected. Not all children will have all symptoms. The most common symptoms include:

  • joint warmth or tenderness
  • pain or stiffness when moving joints
  • limited range of motion
  • stiffness after sleep or rest, and
  • swelling in the joints

Treating JIA

If juvenile idiopathic arthritis is not treated properly, it can affect a child's growth and development. Treatment often begins with over-the-counter drugs and prescription pain relievers. Your doctor may want to try other medications, such as disease-modifying antirheumatic drugs (non-biologic and biologic DMARDs). ENBREL is one type of biologic, indicated to treat moderate to severe polyarticular JIA. Read about results with ENBREL.

Juvenile idiopathic arthritis doesn't just affect the child with the disease. For every child with JIA, there's a family living right alongside him or her—helping that child manage the pain and stiffness. Being the parent of a child with JIA can be an overwhelming responsibility. You have to make decisions that affect your child's health and well-being. Learning more about JIA and its symptoms will help you better understand your child's treatment options.

ENBREL is a prescription medicine that is self-injected. Because ENBREL works on your child's immune system, it can lower his or her ability to fight infections and may raise other safety concerns. If your child has any sign of an infection including a fever, cough, flu-like symptoms, or has any open sores on his or her body, call your child's doctor.

There have also been some cases of unusual cancers reported in children and teenage patients who started using TNF blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA and psoriasis may be more likely to get lymphoma. Please see Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.

Prescription ENBREL is taken by injection.


Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.

Supportive data
Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)
  • In a clinical study, ENBREL was shown to be effective in about 3 out of 4 children with JIA who used it at 3 months. ENBREL has been shown to begin working in as few as 2 to 4 weeks.
Has your child been diagnosed
with JIA?

Sign up today for more information about moderately to severely active JIA and ENBREL.